Navigation Links
Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer
Date:3/6/2013

dge area alone.

"At Sanofi Oncology, our mission goes beyond developing innovative medicines and ensuring their availability," said Debasish Roychowdhury , M.D., Senior Vice President and Head, Sanofi Oncology. "Through initiatives like today's proclamation ceremony, we're educating patients and the public about various cancers, prevention, and treatments, to ultimately promote a healthy way of life in the Cambridge community."

About Colorectal Cancer

In 2010, 142,570 new cases were diagnosed and 51,370 people died from colorectal cancer in the United States. When colorectal cancer is diagnosed at an early stage, the five-year survival rate is nearly 90 percent. However, when the cancer is not diagnosed until a late state, the five-year survival rate is closer to 10 percent. In the past ten years, colon cancer screening rates have increased, but rates still remain low, especially among the uninsured. According to the American Cancer Society, men and women should begin screening for colon cancer at age 50. If the entire population was screened at that age, the number of colorectal cancer-related deaths would be cut in half.

About the Colon Cancer Coalition /Get Your Rear in Gear

Get Your Rear in Gear® events are presented nationally by the Colon Cancer Coalition, a non-profit organization based in Minneapolis. The events are 100% volunteer-driven in communities throughout the United States. The Colon Cancer Coalition distributes funds raised at Get Your Rear in Gear events back into local communities for colon cancer education, prevention, and screening. By making the words colon, colorectal and colonoscopy a part of the everyday language, we believe we can overcome the fear and decrease deaths from this largely preventable cancer.
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PharmaVentures Client Sanofi Wins Scrip Outsourcing Deal of the Year Award
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Collaboration between Sanofi and Joslin Diabetes Center to focus on new drugs for diabetes
5. Sanofi Signs Agreement for Type 1 Diabetes Research with Boston Academic Teaching Hospital
6. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
7. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
8. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
9. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
10. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
11. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... GenoCAD , a platform leveraging the ... announced the formation of its new board of advisors ... a broad range of experience in the biotechnology, pharmaceutical, ... , Jimmy Roussel, Entrepreneur in Residence at The New ... technology and marketing. He has served in operations roles ...
(Date:6/1/2015)... 2015 Research and ... addition of the "Oxidative Stress Assay ... Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020" report ... http://photos.prnewswire.com/prnh/20130307/600769) , The global oxidative ...
(Date:6/1/2015)... GenomeDx Biosciences today announced that ... classified various subtypes of bladder cancer based ... including one type associated with resistance to ... has potential as a tool to predict ... with muscle-invasive bladder cancers (MIBC). The study ...
(Date:6/1/2015)... 2015  Novartis is highlighting data from an ... investigational chimeric antigen receptor (CAR) T cell therapy, ... specific types of hard-to-treat non-Hodgkin lymphoma. Findings from ... Pennsylvania,s Perelman School of Medicine (Penn) in adults ... lymphoma (DLBCL) and follicular lymphoma (FL) found an ...
Breaking Biology Technology:GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... 20 At a meeting of the Board,of Directors of ... of fifty cents($0.50) per share on the outstanding shares of ... of record at the close of business,on December 12, 2008. ... of the world,s largest research-driven pharmaceutical and,health care products companies. ...
... 20 Sigma-Aldrich (Nasdaq: SIAL ),announced today ... iScale,Oligos(TM) siRNA. MISSION(R) In VIVO QUALITY and iScale Oligos(TM) ... next step in their RNAi,research with the highest purity ... These siRNA are believed to be well suited to ...
... Nephros, Inc. (Amex: NEP ), a medical device company developing and marketing ... on its operations and strategy. , , Recent ... , Appointed James Scibetta Chairman of ... III President and CEO , Submitted 510k for ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7
(Date:4/20/2015)... 20, 2015 Huntington Memorial Hospital is the ... a new miniaturized, wireless monitoring sensor to manage heart ... and only FDA-approved heart failure monitoring device that has ... by physicians to manage heart failure. The ... in the pulmonary artery (PA) during a non-surgical procedure ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... a class of small molecules known as microRNA have been ... in most animal and plant species. A new study now ... a hallmark of alcohol abuse and dependence. Researchers supported by ... the findings in the July 31 issue of the journal ...
... July 29, 2008 Two Fortune 500 oil companies ... Engineering at the University of Houston. The funds, from ... Corp., will provide support for a new undergraduate program ... by the Texas Higher Education Coordinating Board this fall. ...
... or cold is not only uncomfortable, it can be ... many years now, scientists have understood the molecular mechanisms ... extremely high temperatures that directly trigger heat sensor proteins ... understood is how animals sense very small temperature differences ...
Cached Biology News:MicroRNA implicated as molecular factor in alcohol tolerance 2Energy industry leaders commit $1.6M to UH petroleum program 2Energy industry leaders commit $1.6M to UH petroleum program 3Summer heat too hot for you? What is comfortable? 2Summer heat too hot for you? What is comfortable? 3